HBIO News & Events

Gross Margin of 60%, at the high end of the 58% to 60% guidance range, driven by an improved mix to higher margin product lines, as well as the benefit of prior cost reductions. Adjusted EBITDA of $3.8M, which reflects 27% growth year over year, driven by cost reduction, improved expense management and solid execution ."We're pleased with our fourth quarter performance and excited to share an overview of our go-forward strategy," said John Duke, CEO. "With a stronger foundation provided by our refinancing and strategic consolidation, we're scaling our business model by focusing our priorities on the evolving needs of the life sciences industry. We are excited for what's ahead and are confident we will drive year over year revenue growth and mid-to high-single digit adjusted EBITDA growth in 2026."

The company said, "As the life sciences industry accelerates toward New Approach Methodologies, Harvard Bioscience is evolving from a traditional tools provider into a leading enabler of Translational Science - uniquely positioned to bridge the gap between laboratory research and human clinical success. Building on its gold-standard preclinical foundation, the Company plans to align its portfolio, innovation pipeline, and operating model around four strategic pillars: Leading the Translational Bridge: bridging in vivo and in vitro research by leveraging the Company's strong preclinical position to facilitate the industry's transition into the organoid and 3D biology markets, improving the translational relevance of early-stage research, and offering customers an integrated solution across critical stages of discovery and development. New Product Introduction Pipeline: modernizing preclinical and translational workflows through differentiated and innovative high-margin platforms such as SoHo telemetry, and proprietary MeshMEA and Incub8 platforms, both of which are designed for organoid and tissue recording. Consumables Revenue Expansion: focusing resources and investments on higher-margin consumables and software with a clear path to increasing mix of recurring revenue from 55% of total revenues currently. Operational Excellence and Disciplined Growth: driving operational excellence and disciplined growth across our global footprint by strengthening our leadership position in the preclinical business. This foundation provides the capital necessary to fuel R&D and strategic bolt-on acquisitions. The Company will also focus on driving consistent profitability by maintaining cost discipline and operational efficiency, supported by its recently announced U.S. manufacturing consolidation and the stronger balance sheet created by last year's debt refinancing."

Harvard Bioscience files to sell 9.5M shares of common stock for holders